CLSD News and Press, Clearside Biomedical Inc. From 03/12/24

Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...

2024-03-11 17:35:46 ET Major earnings expected after the bell on Tuesday include: Clover Health Investments, Corp. ( CLOV ) SurgePays ( SURG ) Heron Therapeutics ( HRTX ) Qifu Technology ( QFIN ) Veritone ( VERI ) Read the full article on Se...

2024-03-11 17:35:35 ET More on Clearside Biomedical Clearside to sell 11.11M shares at $1.35 in registered direct offering Clearside Biomedical reports progress in ODYSSEY Phase 2b trial of CLS-AX Seeking Alpha’s Quant Rating on Clearside Biomedical Hi...

ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its fourth quarter and full year...

2024-02-25 13:37:41 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks . Of course, the excitement goes toward both ext...

2024-02-07 09:29:14 ET More on Clearside Biomedical Clearside Biomedical, Inc. (CLSD) Q3 2023 Earnings Call Transcript Clearside Biomedical reports progress in ODYSSEY Phase 2b trial of CLS-AX Seeking Alpha’s Quant Rating on Clearside Biomedical Histor...

ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ®...

2024-01-22 11:42:05 ET More on Clearside Biomedical Clearside Biomedical reports progress in ODYSSEY Phase 2b trial of CLS-AX BioCryst, Clearside Biomedical in pact for diabetic eye disease Read the full article on Seeking Alpha For further details see: C...

2023-12-14 08:28:42 ET More on Clearside Biomedical Clearside Biomedical, Inc. (CLSD) Q3 2023 Earnings Call Transcript BioCryst, Clearside Biomedical in pact for diabetic eye disease Seeking Alpha’s Quant Rating on Clearside Biomedical Historical earni...

- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s SCS Microinjector ® - - Randomization Completed in ODYSSEY Phase 2b Clinical Trial - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Dec. 14...